Renata Chloupková

Chronic Inflammation as a Potential Predictive Factor of Nivolumab Therapy in Non-small Cell Lung Cancer

Martin Svatoň, Milada Zemanová, Jana Skřičková et al. · Anticancer Research · 2018 · 40 citations · Full text

First-line therapy for T cell lymphomas: a retrospective population-based analysis of 906 T cell lymphoma patients

Andrea Janíková, Renata Chloupková, Vít Campr et al. · Annals of Hematology · 2019 · 33 citations

Hematological Malignancy, Lymphoid Neoplasia, First-line Therapy +12

Change in Serum Lactate Dehydrogenase Is Associated with Outcome of Patients with Advanced-stage NSCLC Treated with Erlotinib.

Ondřej Fiala, Miloš Pešek, Jindřich Fínek et al. · PubMed · 2016 · 24 citations

Regorafenib in the Real-Life Clinical Practice: Data from the Czech Registry

Kateřina Kopečková, Tomáš Büchler, Zbyněk Bortlíček et al. · Targeted Oncology · 2016 · 22 citations

Primary Care, Czech Registry, Patient Safety +9

Thyroid transcription factor 1 expression is associated with outcome of patients with non-squamous non-small cell lung cancer treated with pemetrexed-based chemotherapy

Ondřej Fiala, Miloš Pešek, Jana Skřičková et al. · Tumor Biology · 2017 · 19 citations · Full text

Tumor Biology, Pemetrexed-based Chemotherapy, Medicine +11